Effects of the IL-23–IL-17 pathway on bone in spondyloarthritis
Crossref DOI link: https://doi.org/10.1038/s41584-018-0091-8
Published Online: 2018-09-28
Published Print: 2018-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gravallese, Ellen M.
Schett, Georg
Text and Data Mining valid from 2018-09-28
Article History
First Online: 28 September 2018
Competing interests
: E.M.G. declares that she has received research funding from AbbVie and Eli Lilly. G.S. declares no competing interests.